Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

The PP2A regulator IER5L supports prostate cancer progression

  • Crespo Trives, Jana Roquina
  • Martín Martín, Natalia
  • García Longarte, Saioa
  • Corres Mendizabal, Jon
  • Carlevaris, Onintza
  • Astobiza Pérez, Janire
  • Zabala Letona, Amaia
  • Guiu, Marc
  • Azkargorta, Mikel
  • González López, Monika
  • Macías Cámara, Nuria
  • Doan, Phuong
  • Elortza, Felix
  • Mendizabal, Isabel
  • Westermack, Jukka
  • Gomis, Roger R
  • Ercilla Eguiarte, Amaia
  • Carracedo Pérez, Arkaitz
Prostate cancer exhibits high prevalence and accounts for a high number of cancer-related deaths. The discovery and characterization of molecular determinants of aggressive prostate cancer represents an active area of research. The Immediate Early Response (IER) family of genes, which regulate Protein Phosphatase 2A (PP2A) activity, has emerged among the factors that influence cancer biology. Here, we show that the less studied member of this family, Immediate Early Response 5 like (IER5L), is upregulated in aggressive prostate cancer. Interestingly, the upregulation of IER5L expression exhibits a robust association with metastatic disease in prostate and is recapitulated in other cancer types. In line with this observation, IER5L silencing reduces foci formation, migration and invasion ability in a variety of human and murine prostate cancer cell lines. In vivo, using zebrafish and immunocompromised mouse models, we demonstrate that IER5L-silencing reduces prostate cancer tumor growth, dissemination, and metastasis. Mechanistically, we characterize the transcriptomic and proteomic landscapes of IER5L-silenced cells. This approach allowed us to identify DNA replication and monomeric G protein regulators as downstream programs of IER5L through a pathway that is consistent with the regulation of PP2A. In sum, we report the alteration of IER5L in prostate cancer and beyond and provide biological and molecular evidence of its contribution to tumor aggressiveness., The work of A. Carracedo is supported by Fundación Cris Contra el Cáncer (PR_EX_2021-22), La Caixa Foundation under the agreement LCF/PR/HR17, the Basque Department of Industry, Tourism and Trade (Elkartek), the BBVA foundation (Becas Leonardo), the MICINN (PID2019-108787RB-I00; PID2022-141553OB-I0 (FEDER/EU); Severo Ochoa Excellence Accreditation CEX2021-001136-S), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (GCTRA18006CARR), Vencer el Cáncer Foundation, the iDIFFER network of Excellence (RED2022-134792-T) and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII. AE was supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033 and European Union NextGenerationEU/PRTR. IM is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19). RRG and MG were supported by AECC Grant proyecto GCTRA18006CARR; and MICINN and FEDER funds (CIBERONC and PID2019-104948RB-I00; PID2022-143093OB-100). JW is supported by Finnish Cancer Foundations.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Nanocomposite Scaffolds for Monitoring of Drug Diffusion in Three-Dimensional Cell Environments by Surface-Enhanced Raman Spectroscopy

  • Plou, Javier
  • Molina Martínez, Beatriz
  • García Astrain, Clara
  • Langer, Judith
  • García, Isabel
  • Ercilla Eguiarte, Amaia
  • Perumal, Govindaraj
  • Carracedo Pérez, Arkaitz
  • Liz Marzán, Luis Manuel
[EN]Monitoring dynamic processes in complex cellular environments requires the integration of uniformly distributed detectors within such three-dimensional (3D) networks, to an extent that the sensor could provide real-time information on nearby perturbations in a non-invasive manner. In this context, the development of 3D-printed structures that can function as both sensors and cell culture platforms emerges as a promising strategy, not only for mimicking a specific cell niche but also toward identifying its characteristic physicochemical conditions, such as concentration gradients. We present herein a 3D cancer model that incorporates a hydrogel-based scaffold containing gold nanorods. In addition to sustaining cell growth, the printed nanocomposite inks display the ability to uncover drug diffusion profiles by surface-enhanced Raman scattering, with high spatiotemporal resolution. We additionally demonstrate that the acquired information could pave the way to designing novel strategies for drug discovery in cancer therapy, through correlation of drug diffusion with cell death., J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.-M. acknowledges funding from the European Research Council (Grants ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant MDM-2017-0720). A.C. was funded by MICINN (Grant PID2019-108787RB-I00 (FEDER/EU)) and the European Research Council (ERC Consolidator Grant 819242).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

LUZP1 Controls Cell Division, Migration and Invasion Through Regulation of the Actin Cytoskeleton

  • Bozal Basterra, Laura
  • González Santamarta, María
  • Muratore, Veronica
  • Martín Martín, Natalia
  • Ercilla Eguiarte, Amaia
  • Rodríguez Pérez, José Antonio
  • Carracedo Pérez, Arkaitz
  • Sutherland, James D.
  • Barrio Olano, María Rosa
LUZP1 is a centrosomal and actin cytoskeleton-localizing protein that regulates both ciliogenesis and actin filament bundling. As the cytoskeleton and cilia are implicated in metastasis and tumor suppression, we examined roles for LUZP1 in the context of cancer. Here we show that LUZP1 exhibits frequent genomic aberrations in cancer, with a predominance of gene deletions. Furthermore, we demonstrate that CRISPR/Cas9-mediated loss of Luzp1 in mouse fibroblasts promotes cell migration and invasion features, reduces cell viability, and increases cell apoptosis, centriole numbers, and nuclear size while altering the actin cytoskeleton. Loss of Luzp1 also induced changes to ACTR3 (Actin Related Protein 3, also known as ARP3) and phospho-cofilin ratios, suggesting regulatory roles in actin polymerization, beyond its role in filament bundling. Our results point to an unprecedented role for LUZP1 in the regulation of cancer features through the control of actin cytoskeleton., We are grateful to the Fundacion Inocente, Inocente for their support. We also acknowledge funding by the grants BFU2017-84653-P (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), 765445-EU (UbiCODE Program), SAF2017-90900-REDT (UBIRed Program), and IT1165-19 (Basque Country Government). Additional support was provided by the Department of Industry, Tourism, and Trade of the Basque Country Government (Elkartek Research Programs) and by the Innovation Technology Department of the Bizkaia County. LB-B acknowledges POSTD19048BOZA (Fundacion Cientifica AECC). VM acknowledges PRE2018086230 (MINECO/FEDER, EU). AC acknowledges the Basque Department of education (IKERTALDE IT1106-16), the MCIU [PID2019-108787RB-I00 (FEDER/EU)], the AECC (IDEAS175CARR; GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/and the European Research Council (Starting Grant 336343, PoC 754627, Consolidator grant 819242). CIBERONC was co-funded with FEDER funds. We are also grateful to Maria Vivanco's lab for providing reagents.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Identification of proximal SUMO-dependent interactors using SUMO-ID

  • Barroso Gomila, Orhi
  • Trulsson, Erik
  • Muratore, Veronica
  • Canosa, Iñigo
  • Merino Cacho, Laura
  • Cortázar, Ana Rosa
  • Pérez Fernández, Coralia
  • Azkargorta, Mikel
  • Iloro, Ibon
  • Carracedo Pérez, Arkaitz
  • Aransay Bañares, Ana María
  • Elortza, Felix
  • Mayor Martínez, Ugo
  • Verteegal, Alfred C. O.
  • Barrio Olano, María Rosa
  • Sutherland, James D.
[EN]The fast dynamics and reversibility of posttranslational modifications by the ubiquitin family pose significant challenges for research. Here we present SUMO-ID, a technology that merges proximity biotinylation by TurboID and protein-fragment complementation to find SUMO-dependent interactors of proteins of interest. We develop an optimized split-TurboID version and show SUMO interaction-dependent labelling of proteins proximal to PML and RANGAP1. SUMO-dependent interactors of PML are involved in transcription, DNA damage, stress response and SUMO modification and are highly enriched in SUMO Interacting Motifs, but may only represent a subset of the total PML proximal proteome. Likewise, SUMO-ID also allow us to identify interactors of SUMOylated SALL1, a less characterized SUMO substrate. Furthermore, using TP53 as a substrate, we identify SUMO1, SUMO2 and Ubiquitin preferential interactors. Thus, SUMO-ID is a powerful tool that allows to study the consequences of SUMO-dependent interactions, and may further unravel the complexity of the ubiquitin code., We are thankful to Iraide Escobes for her work in the Proteomics Platform at CIC bioGUNE and Arnoud de Ru in the Center for Proteomics and Metabolomics at the LUMC. O.B.-G., F.T., R.B. and A.C.O.V. acknowledge funding by the grant 765445-EU (UbiCODE Program). R.B. acknowledges funding by grants BFU2017-84653-P and PID2020-114178GB-I00 (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), SAF2017-90900-REDT (UBIRed Program) and IT1165-19 (Basque Country Government). Additional support was provided by the Department of Industry, Tourism, and Trade of the Basque Country Government (Elkartek Research Programs) and by the Innovation Technology Department of the Bizkaia County. VM acknowledges FPI grant PRE2018-086230 (MINECO/FEDER, EU). F.E. is at Proteomics Platform, member of ProteoRed-ISCIII (PT13/0001/0027). F.E. and A.M.A. acknowledge CIBERehd. A.C. acknowledges the Basque Department of education (IKERTALDE IT1106-16), the MCIU (PID2019-108787RB-I00 (FEDER/EU), Severo Ochoa Excellence Accreditation SEV-2016-0644, Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17, and the European Research Council (Starting Grant 336343, PoC 754627, Consolidator grant 819242). CIBERONC was co-funded with FEDER funds. U.M. acknowledges the Basque Government Department of Education (IT1165-19) and the Spanish MCIU (SAF2016-76898-P (FEDER/EU)).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Identification of Androgen Receptor Metabolic Correlome Reveals the Repression of Ceramide Kinase by Androgens

  • Camacho Soguero, Laura
  • Zabala Letona, Amaia
  • Cortázar, Ana Rosa
  • Astobiza Pérez, Janire
  • Domínguez Herrera, Asier
  • Ercilla Eguiarte, Amaia
  • Crespo Trives, Jana Roquina
  • Viera, Cristina
  • Fernández Ruiz, Sonia
  • Martínez González, Ainara
  • Torrano Moya, Verónica
  • Martín Martín, Natalia
  • Gómez Muñoz, Antonio
  • Carracedo Pérez, Arkaitz
Prostate cancer (PCa) is one of the most prevalent cancers in men. Androgen receptor signaling plays a major role in this disease, and androgen deprivation therapy is a common therapeutic strategy in recurrent disease. Sphingolipid metabolism plays a central role in cell death, survival, and therapy resistance in cancer. Ceramide kinase (CERK) catalyzes the phosphorylation of ceramide to ceramide 1-phosphate, which regulates various cellular functions including cell growth and migration. Here we show that activated androgen receptor (AR) is a repressor of CERK expression. We undertook a bioinformatics strategy using PCa transcriptomics datasets to ascertain the metabolic alterations associated with AR activity. CERK was among the most prominent negatively correlated genes in our analysis. Interestingly, we demonstrated through various experimental approaches that activated AR reduces the mRNA expression of CERK: (i) expression of CERK is predominant in cell lines with low or negative AR activity; (ii) AR agonist and antagonist repress and induce CERK mRNA expression, respectively; (iii) orchiectomy in wildtype mice or mice with PCa (harboring prostate-specific Pten deletion) results in elevated Cerk mRNA levels in prostate tissue. Mechanistically, we found that AR represses CERK through interaction with its regulatory elements and that the transcriptional repressor EZH2 contributes to this process. In summary, we identify a repressive mode of AR that influences the expression of CERK in PCa., A.G.-M. is funded by the MINECO (SAF2016-79695-R) and the department of education (IKERTALDE IT1106-16). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia and the Basque Department of Health (2016111109) and the MINECO RTI2018-097267-B-I00. The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the MICINN (PID2019-108787RB-I00 (FEDER/EU); Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer

  • Zabala Letona, Amaia
  • Arruabarrena Aristorena, Amaia
  • Fernández Ruiz, Sonia
  • Viera, Cristina
  • Carlevaris, Onintza
  • Ercilla Eguiarte, Amaia
  • Mendizabal, Isabel
  • Martín Mateos, Teresa
  • Macchia, Alice
  • Camacho Soguero, Laura
  • Pujana Vaquerizo, Mikel
  • Sánchez Mosquera, Pilar
  • Torrano Moya, Verónica
  • Martín Martín, Natalia
  • Zuñiga García, Patricia
  • Castillo Martín, Mireia
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Unda Urzaiz, Jesús Miguel
  • Mato, José M.
  • Berra Ramírez, Miren Edurne
  • Martínez Chantar, María Luz
  • Carracedo Pérez, Arkaitz
[EN] Glycine N-Methyltransferase (GNMT) is a metabolic enzyme that integrates metabolism and epigenetic regulation. The product of GNMT, sarcosine, has been proposed as a prostate cancer biomarker. This enzyme is predominantly expressed in the liver, brain, pancreas, and prostate tissue, where it exhibits distinct regulation. Whereas genetic alterations in GNMT have been associated to prostate cancer risk, its causal contribution to the development of this disease is limited to cell line-based studies and correlative human analyses. Here we integrate human studies, genetic mouse modeling, and cellular systems to characterize the regulation and function of GNMT in prostate cancer. We report that this enzyme is repressed upon activation of the oncogenic Phosphoinositide-3-kinase (PI3K) pathway, which adds complexity to its reported dependency on androgen signaling. Importantly, we demonstrate that expression of GNMT is required for the onset of invasive prostate cancer in a genetic mouse model. Altogether, our results provide further support of the heavy oncogenic signal-dependent regulation of GNMT in prostate cancer., We are grateful to the Carracedo lab for valuable input, to Drs. Ana M. Aransay, James D. Sutherland and F. Elortza for technical advice, and Drs. Michelle Clasquin, Katie Sellers and Katya Marjon at Agios Pharmaceuticals for performing, processing and analyzing the metabolomics experiments. We thank the Basque Biobank for Research (BIOEF) for the support with prostate specimen acquisition and management. A.A-A. was funded by the Basque Government (predoctoral fellowship). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia, the Basque Department of Health (2016111109) and the MICINN RTI2018-097267-B-I00. I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the BBVA foundation, the MICINN (SAF2016-79381-R; PID2019-108787RB-I00 (FEDER/EU); Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), Vencer el Cáncer Foundation, La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Starting Grant 336343, PoC 754627, Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII. We are grateful for the support of Mondravember and Movembergara. A.E. was supported by MCIN/AEI/10.13039/501100011033 and the EU programme NextGenerationEU/PRTR (IJC2020-043583-I). The work of JM Mato was supported by NIH grant R01CA172086 and SAF2017-88041-R. EB is funded by the MICINN (BFU2016-76872-R (FEDER/EU), PID2019-108112RB-I00, and Excellence Networks SAF2017-90794-REDT).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

  • Araujo, Angela M.
  • Abaurrea Larrañaga, Andrea
  • Azcoaga Azcoaga, Peio
  • López Velazco, Joanna Inés
  • Manzano, Sara
  • Rodríguez Martínez, Javier
  • Rezola, Ricardo
  • Egia Mendikute, Leire
  • Valdés Mora, Fátima
  • Flores, Juana M.
  • Jenkins, Liam
  • Pulido, Laura
  • Osorio Querejeta, Iñaki
  • Fernández Nogueira, Patricia
  • Ferrari, Nicola
  • Viera, Cristina
  • Martín Martín, Natalia
  • Tzankov, Alexandar
  • Eppenberger Castori, Serenella
  • Álvarez López, Isabel
  • Urruticoechea, Ander
  • Bragado, Paloma
  • Coleman, Nicholas
  • Palazón García, Francisco de Asís
  • Carracedo Pérez, Arkaitz
  • Gallego Ortega, David
  • Calvo González, Fernando
  • Isacke, Clare M.
  • Muñoz Caffarel, Maria
  • Lawrie, Charles
[EN] The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression., This work was funded by Spanish Ministry of Science and Innovation - ISCIII (PI15/00623, PI18/00458, PI21/01208, CP18/00076, and FI19/00193); European Regional Development (FEDER) funds; Basque Department of Health (2017111011); Fundación SEOM (Beca SEOM-Font Vella); Fundación Gangoiti; and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patient’s charity Katxalin and from Roche Farma S.A. AMA and AA are funded by Basque Government Doctoral Training Grants. JILV is funded by an AECC PhD Fellowship. FVM is supported by the Career Development Fellowship from the Cancer Institute New South Wales (2019/CDF002). AP’s research is funded by the European Research Council (ERC, ERC-2018-StG 804236-NEXTGEN-IO), and by the Spanish Ministry of Science and Innovation (PID2019-107956RA-I00 and RYC2018-024183-I). AC’s research is supported by the Basque Department of Industry, Tourism and Trade (Elkartek); the MICINN (PID2019-108787RB-I00 [FEDER/EU]; Excellence Network (SAF2016-81975-REDT); European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (GCTRA18006CARR), Vencer el Cáncer Foundation; La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/; and the ERC (Consolidator Grant 819242). CIBERONC was cofunded with FEDER funds and funded by ISCIII. DGO is supported by a Cancer Council NSW project grant (RG18-03) and the National Breast Cancer Foundation Elaine Henry Fellowship (IIRS-21-096). FC is funded by Institute of Cancer Research, Spanish Ministry of Science and Innovation (RYC-2016-20352 and RTI2018-096778-A-I00); Asociacion Española Contra el Cancer (LAB-AECC, LABAE19044CALV); and BBVA Leonardo Awards (IN[19]_BBM_BAS_0076).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Metastatic hormone-naïve prostate cancer: a distinct biological entity

  • Corres Mendizabal, Jon
  • Zacchi, Francesca
  • Martín Martín, Natalia
  • Mateo, Joaquín
  • Carracedo Pérez, Arkaitz
Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions., We are thankful to Kathrin Keim for support with English editing. The work of A.C. is supported by the Basque Department of Industry, Tourism, and Trade (Elkartek), the BBVA Foundation (Becas Leonardo), the Ministerio de Ciencia e Innovación (MICINN; PID2022-141553OB-I0 ERDF (European Regional Development Fund)/EU]; the Fundación CRIS Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the Spanish Association Against Cancer (AECC; GCTRA18006CARR), the Fundación Jesús Serra, the iDIFFER Network of Excellence (RED2022-134792-T), the AstraZeneca Award for young scientists (2023 call) and the European Research Council (consolidator grant 819242). CIBERONC was cofunded with FEDER funds and funded by the Instituto de Salud Carlos III (ISCIII). J.M. is supported by a CRIS Talent Award (TALENT20-10) and a Department of Defense Congressionally Directed Medical Research Program (CDMPR) Physician-Science Award (PC220307). VHIO authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the Foundation for Oncological Studies and Research (FERO) and the Centres de Recerca de Catalunya (CERCA) Programme from Generalitat de Catalunya for their support.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Metabolic adaptations in prostate cancer

  • Pujana Vaquerizo, Mikel
  • Bozal Basterra, Laura
  • Carracedo Pérez, Arkaitz
Prostate cancer is one of the most commonly diagnosed cancers in men and is a major cause of cancer-related deaths worldwide. Among the molecular processes that contribute to this disease, the weight of metabolism has been placed under the limelight in recent years. Tumours exhibit metabolic adaptations to comply with their biosynthetic needs. However, metabolites also play an important role in supporting cell survival in challenging environments or remodelling the tumour microenvironment, thus being recognized as a hallmark in cancer. Prostate cancer is uniquely driven by androgen receptor signalling, and this knowledge has also influenced the paths of cancer metabolism research. This review provides a comprehensive perspective on the metabolic adaptations that support prostate cancer progression beyond androgen signalling, with a particular focus on tumour cell intrinsic and extrinsic pathways., We are grateful to the Carracedo lab for valuable input, and to Kathrin Keim for the help with English editing. A. Carracedo is funded by the Basque Department of Industry, Tourism and Trade (Elkartek), the BBVA foundation (Becas Leonardo), the MICINN (PID2022-141553OB-I0 (FEDER/EU); La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17, Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation CEX2021-001136-S), 2023 AstraZeneca Award for Young scientists in oncology, European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), Vencer el Cáncer Foundation, iDIFFER network of Excellence (RED2022-134792-T), Asociación Española Contra el Cáncer (GCTRA18006CARR) and the European Research Council (Consolidator Grant 819242). L. Bozal was supported by the AECC Foundation (POSTD19048BOZA). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Machine learning‐assisted high‐throughput SERS classification of cell secretomes

  • Plou, Javier
  • Valera, Pablo S.
  • García, Isabel
  • Vila Liarte, David
  • Renero Lecuna, Carlos
  • Ruiz Cabello, Jesús
  • Carracedo, Arkaitz
  • Liz Marzán, Luis Manuel
During the response to different stress conditions, damaged cells react in multiple ways, including the release of a diverse cocktail of metabolites. Moreover, secretomes from dying cells can contribute to the effectiveness of anticancer therapies and can be exploited as predictive biomarkers. The nature of the stress and the resulting intracellular responses are key determinants of the secretome composition, but monitoring such processes remains technically arduous. Hence, there is growing interest in developing tools for noninvasive secretome screening. In this regard, it has been previously shown that the relative concentrations of relevant metabolites can be traced by surface-enhanced Raman scattering (SERS), thereby allowing label-free biofluid interrogation. However, conventional SERS approaches are insufficient to tackle the requirements imposed by high-throughput modalities, namely fast data acquisition and automatized analysis. Therefore, machine learning methods were implemented to identify cell secretome variations while extracting standard features for cell death classification. To this end, ad hoc microfluidic chips were devised, to readily conduct SERS measurements through a prototype relying on capillary pumps made of filter paper, which eventually would function as the SERS substrates. The developed strategy may pave the way toward a faster implementation of SERS into cell secretome classification, which can be extended even to laboratories lacking highly specialized facilities., Universidade de Vigo/CISUG, Agencia Estatal de Investigación | Ref. PID2019-108787RB-I00
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga García, Patricia
  • Caro Maldonado, Alfredo
  • Fernandez Ruiz, Sonia
  • Salvador, Fernando
  • Martín Martín, Natalia
  • Zabala Letona, Amaia
  • Nuñez Olle, Marc
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano, José Miguel
  • Talamillo, Ana
  • Carreira, Suzanne
  • Gurel, Bora
  • Cortazar, Ana Rosa
  • Guiu, Marc
  • López, Jose I.
  • Martínez Romero, Anabel
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Lorente, Mar
  • Arruabarrena-Aristorena, Amaia
  • Velasco, Guillermo
  • Gomez Muñoz, Antonio
  • Suarez Cabrera, Cristian
  • Lodewijk, Iris
  • Flores, Juana M.
  • Sutherland, James David
  • Barrio, Rosa
  • Bono, Johann Sebastian de
  • Paramio, Jesús M.
  • Trka, Jan
  • Graupera i Garcia-Milà, Mariona
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkbl alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1(K781), was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiplex SERS Detection of Metabolic Alterations in Tumor Extracellular Media

  • Plou, Javier
  • García, Isabel
  • Charconnet, Mathias
  • Astobiza, Ianire
  • García Astrain, Clara
  • Matricardi, Cristiano
  • Mihi, Agustín
  • Carracedo, Arkaitz
  • Liz-Marzán, Luis Manuel
The composition and intercellular interactions of tumor cells in the tissues dictate the biochemical and metabolic properties of the tumor microenvironment. The metabolic rewiring has a profound impact on the properties of the microenvironment, to an extent that monitoring such perturbations could harbor diagnostic and therapeutic relevance. A growing interest in these phenomena has inspired the development of novel technologies with sufficient sensitivity and resolution to monitor metabolic alterations in the tumor microenvironment. In this context, surface‐enhanced Raman scattering (SERS) can be used for the label‐free detection and imaging of diverse molecules of interest among extracellular components. Herein, the application of nanostructured plasmonic substrates comprising Au nanoparticles, self‐assembled as ordered superlattices, to the precise SERS detection of selected tumor metabolites, is presented. The potential of this technology is first demonstrated through the analysis of kynurenine, a secreted immunomodulatory derivative of the tumor metabolism and the related molecules tryptophan and purine derivatives. SERS facilitates the unambiguous identification of trace metabolites and allows the multiplex detection of their characteristic fingerprints under different conditions. Finally, the effective plasmonic SERS substrate is combined with a hydrogel‐based three‐dimensional cancer model, which recreates the tumor microenvironment, for the real‐time imaging of metabolite alterations and cytotoxic effects on tumor cells., J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496.J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis

  • Shahrouzi, Parastoo
  • Astobiza, Ianire
  • Cortázar, Ana R.
  • Torrano, Verónica
  • Macchia, Alice
  • Flores, Juana María
  • Niespolo, Chiara
  • Mendizábal, Isabel
  • Caloto, Rubén
  • Ercilla, Amaia
  • Camacho, Laura
  • Arreal, Leire
  • Bizkarguenaga, Maider
  • Martínez-Chantar, María Luz
  • Bustelo, Xosé R.
  • Berra, Edurne
  • Kiss-Toth, Endre
  • Velasco, Guillermo
  • Zabala-Letona, Amaia
  • Carracedo, Arkaitz
© 2020 by the authors., Prostate cancer is the most frequent malignancy in European men and the second worldwide. One of the major oncogenic events in this disease includes amplification of the transcription factor cMYC. Amplification of this oncogene in chromosome 8q24 occurs concomitantly with the copy number increase in a subset of neighboring genes and regulatory elements, but their contribution to disease pathogenesis is poorly understood. Here we show that TRIB1 is among the most robustly upregulated coding genes within the 8q24 amplicon in prostate cancer. Moreover, we demonstrate that TRIB1 amplification and overexpression are frequent in this tumor type. Importantly, we find that, parallel to its amplification, TRIB1 transcription is controlled by cMYC. Mouse modeling and functional analysis revealed that aberrant TRIB1 expression is causal to prostate cancer pathogenesis. In sum, we provide unprecedented evidence for the regulation and function of TRIB1 in prostate cancer., We are grateful to the Carracedo lab for valuable input, to Ana M. Aransay and F. Elortza for technical advice. P.S. was funded by the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia, the Basque Department of Health (2016111109) and the MICINN RTI2018-097267-B-I00. A. Macchia was funded by a FPI predoctoral fellowship from MICINN (PRE2018-083607). EB is funded by the MICINN (BFU2016-76872-R (FEDER/EU), PID2019-108112RB-I00, Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2017-90794-REDT). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the BBVA foundation and the MICINN (SAF2016-79381-R (FEDER/EU; PID2019-108787RB-I00) Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2016-81975-REDT and RED2018-102769-T), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Starting Grant 336343, Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Engineering a single-chain immunoglobulin scaffold loaded with a latent-releasable cytotoxic pore-forming peptide

  • Morillo, Izaskun
  • Zulaica, Joao
  • Ramos Caballero, Asier
  • Auzmendi-Iriarte, Jaione
  • Largo, Eneko
  • Apellániz, Beatriz
  • Carracedo, Arkaitz
  • Piva, Marco
  • Nieva, José Luis
  • Rujas, Edurne
Pore-forming peptides (PFPs) hold strong anti-tumor potential but require delivery systems to ensure stability and prevent off-target effects. In this study, we develop a strategy to transport a PFP in a biologically latent, precursor-like state. Specifically, based on the therapeutic antibody atezolizumab, which targets the tumor-associated programmed death-ligand 1, we engineered a single-chain IgG (scIgG) construct with flexible linkers embedding the melittin sequence. To further enable tumor-specific activation, melittin was flanked by regions cleavable by matriptase/ST14 (MT), a protease overexpressed in carcinomas. Initial constructs failed due to cytotoxicity during expression, prompting the redesign of melittin into a variant named Pmod2-2. This peptide retained potent pore-forming ability and was compatible with IgG fusion. The resulting scIgG-Pmod2-2 hybrid preserved Fab and Fc functionalities of the atezolizumab IgG, displayed favorable pharmacokinetics and released the active peptide in response to MT. These results highlight the potential of integrating cytolytic PFPs into antibody-based therapeutics., This study was supported by grants PID2021-126014OB-I00, PID2021-122212OA-I00, PID2022-141200OA-I00, and PID2022-141553OB-I0 (FEDER/EU) funded by MCIN/AEI/10.13039/501100011033/FEDER, UE. Additional support was provided by the European Research Council (Consolidator Grant 819242). J.A. and M.P. acknowledge research contracts from the Ministry of Science and Innovation of Spain (JDC2023-052498-I funded by MICIU/AEI /10.13039/501100011033 and FSE+ and RYC2019-027726-I funded by MICIU/AEI /10.13039/501100011033 and El FSE invierte en tu futuro). I.M. and J.Z. acknowledge predoctoral contracts from the Basque Government, while E.R. received funding from the ERC (grant H2020-MSCA-COFUND-2020-101034228-WOLFRAM2)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SERS analysis of cancer cell-secreted purines reveals a unique paracrine crosstalk in MTAP-deficient tumors

  • Valera, Pablo S.
  • Plou, Javier
  • García, Isabel
  • Astobiza, Ianire
  • Viera, Cristina
  • Aransay, Ana M.
  • Martin, José E.
  • Sasselli, Ivan R.
  • Carracedo, Arkaitz
  • Liz-Marzán, Luis Manuel
RNA Sequencing source data isaccessible at the Gene Expression Omnibus (reference: GSE249082) (46)., [Significance] This research unveils a unique paracrine crosstalk in the tumor microenvironment (TME) involving cancer cells with methylthioadenosine phosphorylase (MTAP) deletions, a common trait linked to poor prognosis. Using surface-enhanced Raman Scattering (SERS), we discovered that these cells secrete 5′-methylthioadenosine (MTA), which can be further metabolized by fibroblasts, leading to molecular changes consistent with cancer aggressiveness and affecting macrophage polarization. Our study not only highlights the potential of SERS for exploring secreted signatures in cancer research but also offers valuable insight to guide more targeted experiments toward deciphering the role of such secreted metabolites in the TME, which could inform future therapeutic strategies., The tumor microenvironment (TME) is a dynamic pseudoorgan that shapes the development and progression of cancers. It is a complex ecosystem shaped by interactions between tumor and stromal cells. Although the traditional focus has been on the paracrine communication mediated by protein messengers, recent attention has turned to the metabolic secretome in tumors. Metabolic enzymes, together with exchanged substrates and products, have emerged as potential biomarkers and therapeutic targets. However, traditional techniques for profiling secreted metabolites in complex cellular contexts are limited. Surface-enhanced Raman scattering (SERS) has emerged as a promising alternative due to its nontargeted nature and simplicity of operation. Although SERS has demonstrated its potential for detecting metabolites in biological settings, its application in deciphering metabolic interactions within multicellular systems like the TME remains underexplored. In this study, we introduce a SERS-based strategy to investigate the secreted purine metabolites of tumor cells lacking methylthioadenosine phosphorylase (MTAP), a common genetic event associated with poor prognosis in various cancers. Our SERS analysis reveals that MTAP-deficient cancer cells selectively produce methylthioadenosine (MTA), which is taken up and metabolized by fibroblasts. Fibroblasts exposed to MTA exhibit: i) molecular reprogramming compatible with cancer aggressiveness, ii) a significant production of purine derivatives that could be readily recycled by cancer cells, and iii) the capacity to secrete purine derivatives that induce macrophage polarization. Our study supports the potential of SERS for cancer metabolism research and reveals an unprecedented paracrine crosstalk that explains TME reprogramming in MTAP-deleted cancers., L.M.L.-M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS). A.C. was funded by Ministerio de Ciencia e Innovación (MICINN) [PID2019-108787RB-I00 Fondo Europeo de Desarrollo Regional (FEDER/EU)] and the European Research Council (ERC Consolidator Grant 819242)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga García, Patricia
  • Caro Maldonado, Alfredo
  • Fernandez Ruiz, Sonia
  • Salvador, Fernando
  • Martín Martín, Natalia
  • Zabala Letona, Amaia
  • Nuñez Olle, Marc
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano, José Miguel
  • Talamillo, Ana
  • Carreira, Suzanne
  • Gurel, Bora
  • Cortazar, Ana Rosa
  • Guiu, Marc
  • López, Jose I.
  • Martínez Romero, Anabel
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Lorente, Mar
  • Arruabarrena-Aristorena, Amaia
  • Velasco, Guillermo
  • Gomez Muñoz, Antonio
  • Suarez Cabrera, Cristian
  • Lodewijk, Iris
  • Flores, Juana M.
  • Sutherland, James David
  • Barrio, Rosa
  • Bono, Johann Sebastian de
  • Paramio, Jesús M.
  • Trka, Jan
  • Graupera i Garcia-Milà, Mariona
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkbl alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1(K781), was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga-García, Patricia
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Fernandez-Ruiz, Sonia
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Zabala-Letona, Amaia
  • Nuñez-Olle, Marc|||0000-0002-3593-2591
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Talamillo, Ana
  • Carreira, Suzanne|||0000-0002-5077-5379
  • Gurel, Bora|||0000-0002-5018-8078
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Guiu, Marc|||0000-0002-7083-986X
  • López, Jose I.|||0000-0003-0842-5348
  • Martinez-Romero, Anabel
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel, Lorea|||0000-0002-7309-9924
  • Lorente, Mar|||0000-0003-0982-0956
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Velasco, Guillermo|||0000-0002-1994-2386
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Suárez-Cabrera, Cristian|||0000-0003-1897-1596
  • Lodewijk, Iris
  • Flores, Juana M.|||0000-0002-7995-4426
  • Sutherland, James D.|||0000-0003-3229-793X
  • Barrio, Rosa|||0000-0002-9663-0669
  • de Bono, Johann S.|||0000-0002-2034-595X
  • Paramio, Jesús M.|||0000-0001-7520-3177
  • Trka, Jan|||0000-0002-9527-8608
  • Graupera, Mariona|||0000-0003-4608-4185
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Carracedo, Arkaitz|||0000-0001-5957-1260
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • Dietmann, Sabine
  • López, Judith
  • Morón-Calvente, Virginia
  • D'Ambrosi, Silvia
  • Nombela, Paz
  • Zamacola, Kepa
  • Mendizabal, Isabel
  • García-Longarte, Saioa
  • Zabala-Letona, Amaia
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Fernández, Sonia
  • Paniagua, Alejandro|||0000-0002-7794-8321
  • Miguel-López, Borja
  • Marchand, Virginie
  • Alonso-López, Diego
  • Merkel, Angelika|||0000-0001-5164-6803
  • García-Tuñón, Ignacio
  • Ugalde-Olano, Aitziber
  • Loizaga-Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Barcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Di Domenico, Tomás
  • Sánchez-Martín, Manuel A.|||0000-0001-8370-1336
  • De Las Rivas, Javier
  • Guil, Sonia|||0000-0002-2257-3331
  • Motorin, Yuri
  • Helm, Mark|||0000-0002-0154-0928
  • Pandolfi, Pier Paolo
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • Blanco, Sandra
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology.